[A22-02] Dapagliflozin (kidney disease) - Addendum to Commission A21-109
Last updated 18.02.2022
Project no.:
A22-02
Commission:
Commission awarded on 11.01.2022 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Kidneys and urinary system
Indication:
Adults with chronic kidney disease
Result of dossier assessment:
Unchanged after addendum:
- Without symptomatic chronic heart failure as comorbidity: hint of considerable added benefit
- With additional symptomatic chronic heart failure as comorbidity: hint of non-quantifiable added benefit
Note:
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
| Project no. | Title | Status |
|---|---|---|
| A21-109 | Dapagliflozin (kidney disease) - Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2022-02-18 A G-BA decision was published.